Whittier Trust Co. of Nevada Inc. decreased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 4.9% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 151,037 shares of the healthcare product maker’s stock after selling 7,794 shares during the quarter. Abbott Laboratories comprises about 0.9% of Whittier Trust Co. of Nevada Inc.’s portfolio, making the stock its 29th biggest holding. Whittier Trust Co. of Nevada Inc.’s holdings in Abbott Laboratories were worth $12,074,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc lifted its position in Abbott Laboratories by 1.6% in the third quarter. Vanguard Group Inc now owns 139,012,321 shares of the healthcare product maker’s stock valued at $10,197,944,000 after buying an additional 2,208,781 shares during the last quarter. BlackRock Inc. lifted its position in Abbott Laboratories by 3.3% in the fourth quarter. BlackRock Inc. now owns 121,045,590 shares of the healthcare product maker’s stock valued at $8,755,228,000 after buying an additional 3,842,101 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its position in Abbott Laboratories by 7,559.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 30,095,862 shares of the healthcare product maker’s stock valued at $416,000 after buying an additional 29,702,943 shares during the last quarter. Northern Trust Corp lifted its position in Abbott Laboratories by 2.7% in the fourth quarter. Northern Trust Corp now owns 26,603,904 shares of the healthcare product maker’s stock valued at $1,924,260,000 after buying an additional 708,691 shares during the last quarter. Finally, FMR LLC lifted its position in Abbott Laboratories by 118.2% in the fourth quarter. FMR LLC now owns 23,762,285 shares of the healthcare product maker’s stock valued at $1,718,726,000 after buying an additional 12,871,418 shares during the last quarter. 73.42% of the stock is owned by institutional investors and hedge funds.

Shares of ABT traded up $0.50 during mid-day trading on Wednesday, hitting $81.62. 114,372 shares of the company’s stock were exchanged, compared to its average volume of 5,821,210. The stock has a market capitalization of $142.44 billion, a PE ratio of 28.32, a P/E/G ratio of 2.27 and a beta of 1.08. Abbott Laboratories has a fifty-two week low of $60.31 and a fifty-two week high of $82.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.13 and a current ratio of 1.58.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, April 17th. The healthcare product maker reported $0.63 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.61 by $0.02. The business had revenue of $7.54 billion for the quarter, compared to analysts’ expectations of $7.49 billion. Abbott Laboratories had a net margin of 8.53% and a return on equity of 16.86%. The business’s quarterly revenue was up 2.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.59 earnings per share. On average, sell-side analysts predict that Abbott Laboratories will post 3.22 earnings per share for the current year.

In related news, SVP Jaime Contreras sold 918 shares of the company’s stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $73.12, for a total transaction of $67,124.16. Following the sale, the senior vice president now directly owns 34,706 shares in the company, valued at $2,537,702.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian J. Blaser sold 450,062 shares of the company’s stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $75.52, for a total transaction of $33,988,682.24. Following the sale, the insider now owns 295,745 shares in the company, valued at $22,334,662.40. The disclosure for this sale can be found here. Insiders have sold 980,493 shares of company stock worth $74,796,843 in the last three months. Corporate insiders own 0.70% of the company’s stock.

A number of research firms have commented on ABT. Zacks Investment Research cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating and set a $84.00 target price on the stock. in a research report on Friday, June 7th. William Blair reaffirmed an “outperform” rating on shares of Abbott Laboratories in a research report on Thursday, April 18th. Royal Bank of Canada upped their target price on shares of Abbott Laboratories to $82.00 and gave the company a “buy” rating in a research report on Monday, April 15th. They noted that the move was a valuation call. Wells Fargo & Co reaffirmed a “buy” rating on shares of Abbott Laboratories in a research report on Thursday, March 14th. Finally, Barclays set a $84.00 target price on shares of Abbott Laboratories and gave the company a “buy” rating in a research report on Friday, March 8th. One analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $80.24.

ILLEGAL ACTIVITY WARNING: “Whittier Trust Co. of Nevada Inc. Reduces Stake in Abbott Laboratories (NYSE:ABT)” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/whittier-trust-co-of-nevada-inc-reduces-stake-in-abbott-laboratories-nyseabt/3039548.html.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Featured Story: What is the Moving Average Convergence Divergence (MACD) oscillator?

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.